Hajime Kuroda1,2, Tsengelmaa Jamiyan3,4, Rin Yamaguchi5, Akinari Kakumoto6,7, Akihito Abe8, Oi Harada9, Atsuko Masunaga6. 1. Department of Diagnostic Pathology, Tokyo Women's Medical University, Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo, 116-8567, Japan. kuroda.hajime@twmu.ac.jp. 2. Department of Diagnostic Pathology, Dokkyo Medical University, Mibu, Japan. kuroda.hajime@twmu.ac.jp. 3. Department of Diagnostic Pathology, Dokkyo Medical University, Mibu, Japan. 4. Department of Pathology and Forensic Medicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia. 5. Department of Pathology & Laboratory Medicine, Kurume University Medical Center, Kurume, Japan. 6. Department of Diagnostic Pathology, Tokyo Women's Medical University, Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo, 116-8567, Japan. 7. Department of Diagnostic Pathology, Nasu Red Cross Hospital, Otawara, Japan. 8. Breast Center, Dokkyo Medical University, Mibu, Japan. 9. Breast center, Showa University, Tokyo, Japan.
Abstract
BACKGROUND: In this study, we investigated CD20+ TILs in triple-negative breast cancer (TNBC) and their relationship with T lymphocyte subsets (CD4+, CD8+, CD25+, and FOXP3+), including their combined prognostic value using an immunohistochemical staining method. METHODS: We investigated 107 patients with TNBC for whom a full-face section stained by hematoxylin and eosin between 2006 and 2018 at Dokkyo Medical University Hospital was available. RESULTS: The strongest association of infiltrating CD20+ TILs was with CD4+ TILs. There was a significant relationship between CD20+ and CD4+ TILs (r = 0.177; p < 0.001), CD8+ TILs (r = 0.085; p = 0.002), and FOXP3+ TILs (r = 0.0043; p = 0.032). No significant relationships were observed between the CD20+ and CD25+ TILs (r = 0.012; p = 0.264). Multivariate analysis revealed that only the CD20+/FOXP3 ratio was an independent factor for relapse-free survival (p < 0.001) and overall survival (p < 0.001). Patients with tumors highly infiltrated by CD4+, CD8+, and CD20+ TILs had a good prognosis. In contrast, those with tumors weakly infiltrated by CD20+ TILs but highly infiltrated by CD25+ and FOXP3+ TILs had a poor prognosis. CONCLUSIONS: CD20+ TILs may support an increase in CD4+ and CD8+ TILs, which altered the anti-tumor response, resulting in a positive prognosis. CD20+ TILs correlated with FOXP3+ Treg lymphocytes, which were reported to be correlated with a poor prognosis. Our study suggested that TIL-B cells have dual and conflicting roles in TIL-T immune reactions in TNBC.
BACKGROUND: In this study, we investigated CD20+ TILs in triple-negative breast cancer (TNBC) and their relationship with T lymphocyte subsets (CD4+, CD8+, CD25+, and FOXP3+), including their combined prognostic value using an immunohistochemical staining method. METHODS: We investigated 107 patients with TNBC for whom a full-face section stained by hematoxylin and eosin between 2006 and 2018 at Dokkyo Medical University Hospital was available. RESULTS: The strongest association of infiltrating CD20+ TILs was with CD4+ TILs. There was a significant relationship between CD20+ and CD4+ TILs (r = 0.177; p < 0.001), CD8+ TILs (r = 0.085; p = 0.002), and FOXP3+ TILs (r = 0.0043; p = 0.032). No significant relationships were observed between the CD20+ and CD25+ TILs (r = 0.012; p = 0.264). Multivariate analysis revealed that only the CD20+/FOXP3 ratio was an independent factor for relapse-free survival (p < 0.001) and overall survival (p < 0.001). Patients with tumors highly infiltrated by CD4+, CD8+, and CD20+ TILs had a good prognosis. In contrast, those with tumors weakly infiltrated by CD20+ TILs but highly infiltrated by CD25+ and FOXP3+ TILs had a poor prognosis. CONCLUSIONS:CD20+ TILs may support an increase in CD4+ and CD8+ TILs, which altered the anti-tumor response, resulting in a positive prognosis. CD20+ TILs correlated with FOXP3+ Treg lymphocytes, which were reported to be correlated with a poor prognosis. Our study suggested that TIL-B cells have dual and conflicting roles in TIL-T immune reactions in TNBC.
Entities:
Keywords:
Breast; Triple-negative cancer; Tumor-infiltrating B lymphocytes; Tumor-infiltrating T lymphocytes
Authors: Kimberly H Allison; M Elizabeth H Hammond; Mitchell Dowsett; Shannon E McKernin; Lisa A Carey; Patrick L Fitzgibbons; Daniel F Hayes; Sunil R Lakhani; Mariana Chavez-MacGregor; Jane Perlmutter; Charles M Perou; Meredith M Regan; David L Rimm; W Fraser Symmans; Emina E Torlakovic; Leticia Varella; Giuseppe Viale; Tracey F Weisberg; Lisa M McShane; Antonio C Wolff Journal: J Clin Oncol Date: 2020-01-13 Impact factor: 44.544
Authors: Marcus Schmidt; Daniel Böhm; Christian von Törne; Eric Steiner; Alexander Puhl; Henryk Pilch; Hans-Anton Lehr; Jan G Hengstler; Heinz Kölbl; Mathias Gehrmann Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Koichi Yanaba; Jean-David Bouaziz; Takashi Matsushita; Cynthia M Magro; E William St Clair; Thomas F Tedder Journal: Immunol Rev Date: 2008-06 Impact factor: 12.988
Authors: S M A Mahmoud; A H S Lee; E C Paish; R D Macmillan; I O Ellis; A R Green Journal: Breast Cancer Res Treat Date: 2011-06-14 Impact factor: 4.872
Authors: Young Mo Kang; Xiaoyu Zhang; Ulf G Wagner; Hongyu Yang; Robert D Beckenbaugh; Paul J Kurtin; Jörg J Goronzy; Cornelia M Weyand Journal: J Exp Med Date: 2002-05-20 Impact factor: 14.307
Authors: Renata Ariza Marques Rossetti; Noely Paula Cristina Lorenzi; Kaori Yokochi; Maria Beatriz Sartor de Faria Rosa; Luciana Benevides; Paulo Francisco Ramos Margarido; Edmund Chada Baracat; Jesus Paula Carvalho; Luisa Lina Villa; Ana Paula Lepique Journal: PLoS One Date: 2018-07-05 Impact factor: 3.240
Authors: Marta Garnelo; Alex Tan; Zhisheng Her; Joe Yeong; Chun Jye Lim; Jinmiao Chen; Kiat Hon Lim; Achim Weber; Pierce Chow; Alexander Chung; London Lucien Pj Ooi; Han Chong Toh; Mathias Heikenwalder; Irene O L Ng; Alessandra Nardin; Qingfeng Chen; Jean-Pierre Abastado; Valerie Chew Journal: Gut Date: 2015-12-15 Impact factor: 23.059
Authors: Marcus Schmidt; Veronika Weyer-Elberich; Jan G Hengstler; Anne-Sophie Heimes; Katrin Almstedt; Aslihan Gerhold-Ay; Antje Lebrecht; Marco J Battista; Annette Hasenburg; Ugur Sahin; Konstantine T Kalogeras; Pirkko-Liisa Kellokumpu-Lehtinen; George Fountzilas; Ralph M Wirtz; Heikki Joensuu Journal: Breast Cancer Res Date: 2018-02-26 Impact factor: 6.466
Authors: Vinay Kumar; Pavneet Randhawa; Robert Bilodeau; Dan Mercola; Michael McClelland; Anshu Agrawal; James Nguyen; Patricia Castro; Michael M Ittmann; Farah Rahmatpanah Journal: Cancers (Basel) Date: 2022-10-08 Impact factor: 6.575